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LKB1, the product of a tumour suppressor gene, is a
serine/threonine kinase that coordinates disparate
cellular processes. Recent data have revealed novel
functions for LKB1, providing new insight into the
regulation of cell polarity and energy-generating
metabolism.
Like most tumour suppressor genes, LKB1 was
identified because inactivating germ-line mutations in
the gene are associated with inherited cancer sus-
ceptibility. Heterozygous pathogenic LKB1 mutations
are found in many patients affected by Peutz-Jeghers
syndrome [1,2], a defining hallmark of which is the
acquisition of benign intestinal polyps known as hamar-
tomas. Peutz-Jeghers syndrome individuals are highly
prone to colorectal and a range of other cancers, which
usually display loss of the wild-type LKB1 allele. This
gene is also somatically inactivated in some sporadic
tumours occurring in individuals without a familial pre-
disposition. LKB1 encodes a protein kinase to which a
variety of functions have been ascribed [3], but as yet no
individual hypothesis has convincingly explained how
loss of LKB1 function contributes to carcinogenesis.
Recently, however, the LKB1 protein has been shown
to be involved in two biologically critical pathways;
dysfunction of both of these pathways may be important
in the pathogenesis of Peutz-Jeghers syndrome. First
[4], LKB1 has been shown to play a fundamental role in
controlling the spatial orientation of structures required
to maintain an ordered, polarised epithelium (Figure 1).
And second [5–7], LKB1 activity has been suggested to
be the elusive master regulator of AMP-dependent
kinase (AMPK), which controls the balance of cellular
energy consumption and generation (Figure 1).
All epithelial surfaces are dependent for their
structure and function on planar polarity. By way of par-
adigm, the intestine is lined by a monolayer of polarised
columnar cells, having an apical brush border that pro-
vides a large surface area for the transport of elec-
trolytes and nutrients from the gut lumen into the cell.
Such polarisation was previously thought to require
cell–cell interaction in a confluent monolayer, perhaps
through interruption of the diffusion of membrane pro-
teins by tight junctions. Surprisingly, however, it now
transpires that a single cell can become polarised
simply through the activation of LKB1 [4].
Initial studies of LKB1 were hampered by an
apparent lack of kinase activity when the protein was
tested against a wide range of substrates. Recently,
however, it has been shown that the pseudokinase
STRAD associates with, and activates, LKB1 [8]. This
unlocking of the cryptic activity of LKB1 has allowed
the controlled expression of kinase activity in gut
epithelial cells by manipulating levels of STRAD. This
results in the reorganisation of non-polarised cells so
that they form asymmetrical apical and basal struc-
tures, including a brush border [4]. Polarisation occurs
despite the absence of contact with neighbouring cells,
and even in cells in suspension. Conversely, depletion
of LKB1 in intestinal epithelial cells prevents normal
polarisation when the cells form a confluent monolayer. 
The mechanism by which LKB1 induces polarisation
may involve another group of mammalian serine/
threonine kinases, collectively termed the PAR1 family.
LKB1 associates with PAR1 [9] and causes its phos-
phorylation and activation [10,11]. Expression of a dom-
inant-negative PAR1 in mammalian cells growing in a
polarised confluent sheet disrupts the planar symmetry
of the epithelium, resulting in heaping up of cells [12].
Such a process could easily contribute to the trans-
formed phenotype in cells where PAR1 activity is
impaired by loss of functional LKB1.
The interplay between LKB1 and PAR1 has also been
documented in non-mammalian systems. The equiva-
lent of LKB1 in the nematode worm Caenorhabditis
elegans was classified within the ‘partitioning defective’
(Par) group of genes, which are implicated in the regu-
lation of asymmetric cell division in the early embryo;
Par4 appears to be the worm LKB1 orthologue. The
phenotypic effects of inactivating Par4/LKB1 or Par1
are similar, suggesting that the two protein products of
these genes cooperate in a kinase cascade in this
organism too [13]. Similarly, Drosophila PAR1 functions
to establish polarity of the fly egg chamber and embryo,
and the consequence of loss of LKB1 activity is disrup-
tion of the normal polarised cell morphology in epithe-
lial follicle cells [14]. Furthermore, overexpression of
LKB1 can partially rescue the par1 mutant phenotype.
These results, in worms and flies further re-inforce the
connection between the LKB1 and PAR1 kinases in the
regulation of cell polarity.
How does the LKB1/PAR1 cascade interact with the
cellular machinery to generate polarity? Cell
polarisation requires asymmetry in the localisation of
structural components including microtubules, and it
may be that these structures are targeted by LKB1, via
PAR1. In support of this, two members of the mam-
malian PAR1 family were initially characterised in a
screen for kinases able to phosphorylate microtubule-
associated proteins [15], an event which destabilises
microtubules and leads to their dissociation into
tubulin subunits. The coordinated dissociation and re-
association of tubulin is essential to asymmetric micro-
tubular function in a number of processes including
mitotic spindle formation. As well as effects on cellular
polarity, downregulation of proliferative signalling may
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be a consequence of PAR1 acting downstream from
LKB1. PAR1 is known to phosphorylate and activate
Dishevelled [16], a key component of the Wnt pathway
that is upregulated in most colorectal cancers. So
LKB1 might regulate Wnt signalling through its inter-
action with PAR1, and some recent observations
support this conjecture [10,17].
There is increasing evidence that LKB1 is a master
kinase which, when associated with STRAD, can phos-
phorylate a number of mammalian kinases related in
sequence to PAR1 [11]. Of particular importance is the
demonstration, by several groups [5–7], that LKB1 is an
activating upstream kinase for AMPK. AMPK plays a
key role in controlling the energy charge of the cell, and
an upstream AMPK kinase has long been sought. LKB1
and STRAD co-purify with a cellular extract that phos-
phorylates and dramatically activates AMPK in vitro [5].
This unexpected result has been convincingly con-
firmed in cells; agents such as H2O2 activate AMPK in
wild-type mouse embryonic fibroblasts, but not in cells
lacking LKB1 [5–7].
Phosphorylation and activation of AMPK redirects
cell metabolism towards generation of ATP, and away
from energy-requiring macromolecular synthesis such
as that required for cell division [18]. Therefore cells in
which LKB1 activity has been lost may enjoy a
proliferative advantage (Figure 1). The mechanisms by
which neoplastic cells activate catabolic pathways to
fuel cell division have been little studied. Although
there are precedents for the switching on of ‘house-
keeping’ functions, such as tRNA transcription, in the
transformed phenotype [19], this link between a
tumour suppressor gene and such a central metabolic
process is an exciting development.
The control of protein synthesis by AMPK occurs, at
least in part, via mammalian target of rapamycin
(mTOR), a kinase which is inhibited following
phosphorylation of TCS2 (also known as tuberin) by
AMPK [20]. Through this pathway, loss of LKB1 activity
in hamartomas would release the inhibition of protein
translation facilitating cell growth and proliferation
(Figure 1). Provocatively, germ-line TSC2 mutations are
found in tuberous sclerosis, another inherited syndrome
having hamartomatous polyps as part of the phenotype.
Therefore mis-regulation of the AMPK–mTOR–TSC2
pathway might provide an explanation for the similari-
ties in the histology of the benign hamartomas seen in
both Peutz-Jeghers syndrome and tuberous sclerosis.
These insights into LKB1 function suggest future
new avenues for anti-cancer therapy, either through
restoration of appropriate cell polarisation in cells that
have lost functional LKB1, or by the modification of
AMPK activity. Metformin, the most widely prescribed
oral hypoglycaemic used in the treatment of diabetes,
is an activator of AMPK; metformin-related drugs
might therefore find application as anti-proliferative
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Figure 1. LKB1 kinase activity coordinates diverse cellular processes.
(A) Both AMPK and PAR1 are phosphorylated and activated by LKB1. LKB1-directed PAR1 activation promotes correct polarisation,
including brush border formation in an intestinal epithelial cell. In parallel, AMPK redirects metabolic priorities towards the genera-
tion of ATP, and downregulates anabolic processes, including protein synthesis. Metformin is an activator of AMPK used in the treat-
ment of diabetes. Rapamycin is an inhibitor of mTOR. (B) Absence of LKB1 results in failure of PAR1 activation and loss of cell polarity.
In addition, failure of AMPK activation releases inhibition of mTOR, switching on anabolic pathways required for cell division.
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agents in certain cancers. Furthermore, inhibitors of
mTOR are already in clinical development. Conversely,
modification of the activity of the LKB1 may prove
useful in the treatment of diabetes.
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